Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous fecal microbiota transplantation (University of Amsterdam)
- Development stage
- Unknown
- Lead developer
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Cell Therapies, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Autologous fecal microbiota transplantation (FMT) is an investigational therapy being developed by the University of Amsterdam for type 1 diabetes mellitus. [2, 3] The treatment consists of freeze-dried fecal matter from the patient (autologous), which is placed in capsules for daily oral administration. [3, 4] The underlying principle is that modulating the patient's intestinal microbiota can help preserve the function of remaining insulin-producing beta cells in individuals recently diagnosed with type 1 diabetes, an autoimmune disease. [3, 7] A proof-of-concept study and a subsequent single-arm pilot study (ENCAPSULATE-DM1) suggested the approach is safe and may halt the decline of beta-cell function. [2, 4, 8] A larger, Phase 2 placebo-controlled trial, FACT-T1D, is planned to confirm these findings. [3]
- Other names
- autologous fecal microbiota transplantation-Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)-type 1 diabetes mellitusautologous faecal microbiota transplantationencapsulated autologous FMTautologous lyophilized fecal microbiota capsules
Beyond the preview
Go deeper on autologous fecal microbiota transplantation (University of Amsterdam).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous fecal microbiota transplantation (University of Amsterdam).